Skip to main content
. Author manuscript; available in PMC: 2019 Oct 18.
Published in final edited form as: Clin Cancer Res. 2018 Oct 2;25(1):290–299. doi: 10.1158/1078-0432.CCR-18-2311

Figure 5.

Figure 5.

In vivo viral gene and scFvPD-1 expression after GBM treatment with NG34scFvPD-1. C57Bl/6 mice were intracranially injected with GL261N4 cells (105 cells). After 7 days, NG34scFvPD-1 was intracranially administered at a dose of 1.5 × 106 pfu/mouse. Sixteen, 36, and 60 hours after virus inoculation, mice were sacrificed, their brains harvested, and RNA isolated. scFvPD-1 (A) and immediate early gene (ICP4) and late gene (gD) mRNA copy number were assessed by real-time PCR (B). One-way ANOVA (Tukey multiple comparisons test) was used for the analyses (*, P < 0.05; **, P < 0.01).